A study analysing whether application of anti-PD1 drugs before or during thoracic radiotherapy increases the incidence of radiation pneumonia compared to the application after radiotherapy
Latest Information Update: 07 Oct 2020
At a glance
- Drugs Camrelizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Sintilimab (Primary) ; Toripalimab (Primary)
- Indications Cancer
- Focus Adverse reactions
- 07 Oct 2020 New trial record
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress